Liu Yanhao, Yu Lan, Liang Yanjiao, Cheng Xi, Jiang Shu, Yu Haiming, Zhang Zhen, Lu Linlin, Qu Baozhen, Chen Yuxian, Zhang Xiaotao
Department of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Front Oncol. 2023 Jan 9;12:1024179. doi: 10.3389/fonc.2022.1024179. eCollection 2022.
Immunotherapy for lung cancer has been a hot research area for years. This bibliometric analysis was intended to present research trends on melanoma immunotherapy.
On April 1, 2022, the authors identified 2,109 papers on melanoma immunotherapy using the Web of Science and extracted their general information and the total number of citations. The authors then conducted a bibliometric analysis to present the research landscape, clarify the research trends, and determine the most cited papers (top-papers) as well as major journals on melanoma immunotherapy. Subsequently, recent research hotspots were identified by analyzing the latest articles in major journals.
The total and median number of citations of these 2,109 papers on melanoma immunotherapy was 137,686 and 11, respectively. "Improved survival with ipilimumab in patients with metastatic melanoma" by Hodi et al. was the most cited paper (9,824 citations). Among the journals, the top-paper number (16), average citations per paper (2,510.7), and top-papers rate (100%) of were the highest. Corresponding authors represented the USA took part in most articles (784). Since 2016, the hottest research area has changed from CTLA-4 to PD-1.
This bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on 2,109 relevant publications, and further suggests future research directions. The researchers can benefit in selecting journals and in finding potential collaborators. This study can help researchers gain a comprehensive impression of the research landscape, historical development, and current hotspots in melanoma immunotherapy and can provide inspiration for future research.
肺癌免疫疗法多年来一直是热门研究领域。这项文献计量分析旨在呈现黑色素瘤免疫疗法的研究趋势。
2022年4月1日,作者使用科学网识别出2109篇关于黑色素瘤免疫疗法的论文,并提取其一般信息和总被引次数。然后作者进行文献计量分析,以呈现研究概况、阐明研究趋势,并确定黑色素瘤免疫疗法中被引次数最多的论文(高被引论文)以及主要期刊。随后,通过分析主要期刊上的最新文章确定了近期研究热点。
这2109篇关于黑色素瘤免疫疗法的论文的总被引次数和中位数分别为137686次和11次。霍迪等人发表的“伊匹单抗改善转移性黑色素瘤患者的生存率”是被引次数最多的论文(9824次)。在这些期刊中,[期刊名称未给出]的高被引论文数量(16篇)、每篇论文的平均被引次数(2510.7次)和高被引论文率(100%)最高。通讯作者来自美国的文章参与度最高(784篇)。自2016年以来,最热门的研究领域已从CTLA - 4转变为PD - 1。
这项文献计量分析基于2109篇相关出版物全面且定量地呈现了研究趋势和热点,并进一步提出了未来的研究方向。研究人员在选择期刊和寻找潜在合作者方面会有所受益。本研究有助于研究人员全面了解黑色素瘤免疫疗法的研究概况、历史发展和当前热点,并能为未来研究提供灵感。